NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $112.36 -4.44 (-3.80%) Closing price 04:00 PM EasternExtended Trading$112.44 +0.08 (+0.07%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$112.00▼$117.0150-Day Range$86.17▼$119.0452-Week Range$74.50▼$122.20Volume1.50 million shsAverage Volume869,978 shsMarket Capitalization$7.79 billionP/E RatioN/ADividend YieldN/APrice Target$141.67Consensus RatingModerate Buy Company Overview Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies. Rhythm also studies setmelanotide in other conditions involving disruption of the body’s appetite-regulation pathways. Rhythm was founded in 2008 and is led by Chief Executive Officer David Meeker. The company’s activities include research and development, clinical trials, and efforts to expand access to its treatment for patients with rare disorders.AI Generated. May Contain Errors. Read More Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreRYTM MarketRank™: 2.27491078781 of 5 starsRhythm Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 551st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 18 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialRhythm Pharmaceuticals has a consensus price target of $141.67, representing about 26.1% upside from its current price of $112.36.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.90) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -38.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -38.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 88.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.90% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 23.33, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 6.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.23 News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,850,246.00 in company stock.Percentage Held by Insiders5.90% of the stock of Rhythm Pharmaceuticals is held by insiders.Percentage Held by InstitutionsRhythm Pharmaceuticals has minimal institutional ownership at this time.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RYTM Stock News HeadlinesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesNovember 19 at 4:45 AM | americanbankingnews.comRhythm Stock Is Up 32%. Is One Drug Enough?November 18 at 11:08 AM | finance.yahoo.comA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.November 20 at 1:00 AM | Monetary Gold (Ad)Rhythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVRNovember 18 at 6:07 AM | seekingalpha.comRythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVRNovember 18 at 6:07 AM | msn.comRhythm drug shows sustained weight reduction in patients with brain damage-related obesityNovember 16, 2026 | msn.comRhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026November 16, 2026 | globenewswire.comRhythm Pharmaceuticals Earnings Call Signals Strong Growth AheadNovember 15, 2026 | theglobeandmail.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $107.04 at the start of the year. Since then, RYTM shares have increased by 5.0% and is now trading at $112.36. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its earnings results on Tuesday, November, 3rd. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.10. The firm's revenue was up 79.6% compared to the same quarter last year. Read the conference call transcript. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $106 million in an IPO on Thursday, October 5th 2017. The company issued 7,050,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Top institutional investors of Rhythm Pharmaceuticals include State Street Corp (3.81%), Goldman Sachs Group Inc. (3.05%), Checkpoint Capital L.P. (1.75%) and Pictet Asset Management Holding SA (1.42%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Jennifer Kayden Lee, Pamela J Cramer, Joseph Shulman, Christophe Jean, Lynn A Tetrault, Jennifer L Good, Alastair Garfield and Christopher Paul German. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Eli Lilly and Company (LLY), Palantir Technologies (PLTR), Tesla (TSLA), Viking Therapeutics (VKTX) and NIO (NIO). Company Calendar Last Earnings11/03/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, RYTM's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RYTM CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees414Year Founded2008Price Target and Rating Average Price Target for Rhythm Pharmaceuticals$141.67 High Price Target$160.00 Low Price Target$114.00 Potential Upside/Downside+26.1%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($2.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.54 million Net Margins-69.03% Pretax Margin-68.47% Return on Equity-171.16% Return on Assets-43.00% Debt Debt-to-Equity RatioN/A Current Ratio2.78 Quick Ratio2.57 Sales & Book Value Annual Sales$189.76 million Price / Sales41.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book88.47Miscellaneous Outstanding Shares69,330,000Free Float65,240,000Market Cap$7.79 billion OptionableOptionable Beta2.17 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RYTM) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.